Suppliers and packagers for FOCALIN XR

FOCALIN XR

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802	NDA	Novartis Pharmaceuticals Corporation	0078-0430-05	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0078-0430-05)	2005-05-31
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802	NDA	Novartis Pharmaceuticals Corporation	0078-0431-05	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0078-0431-05)	2005-05-31
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802	NDA	Novartis Pharmaceuticals Corporation	0078-0432-05	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0078-0432-05)	2005-05-31
Sandoz	FOCALIN XR	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021802	NDA	Novartis Pharmaceuticals Corporation	0078-0433-05	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0078-0433-05)	2005-05-31

Suppliers for the Pharmaceutical Drug: FOCALIN XR

Last updated: August 17, 2025

---

Introduction

Focalin XR (dexmethylphenidate extended-release) is a widely prescribed medication for Attention Deficit Hyperactivity Disorder (ADHD). As a formulation of dexmethylphenidate—an active enantiomer of methylphenidate—its manufacturing and supply chain encompass multiple pharmaceutical suppliers globally. Ensuring a robust understanding of its suppliers is crucial for stakeholders involved in procurement, supply chain management, and regulatory compliance.

This article comprehensively examines the key suppliers of Focalin XR, analyzing manufacturing sources, procurement channels, and regulatory considerations influencing its availability.

---

Manufacturing Origins and Key Suppliers

1. Primary Manufacturer: Novartis Pharmaceuticals

Novartis Pharmaceuticals has historically been the originator of Focalin XR, innovating its formulation to provide extended-release benefits. The drug is primarily produced within Novartis's manufacturing facilities, which adhere to stringent Good Manufacturing Practice (GMP) standards.

• Manufacturing Locations: Novartis’s facilities involved in Focalin XR production are predominantly situated in markets with established pharmaceutical manufacturing infrastructure, including the United States and Switzerland. These facilities are FDA- and EMA-approved, ensuring product quality and regulatory compliance.

• Supply Chain Role: Novartis supplies Focalin XR directly to wholesalers, pharmacy chains, and government procurement agencies. The company ensures stability through strategic inventory management and global distribution agreements.

2. Contract Manufacturing and Toll Manufacturing

While Novartis maintains control over core production, certain aspects of Focalin XR manufacturing may involve contract manufacturing organizations (CMOs) globally.

• CMOs in Asia and Europe: Several CMOs in India, China, and Eastern Europe are capable of producing active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) under licensing agreements with Novartis. These CMOs provide capacity flexibility but operate under strict quality contracts aligned with international regulatory standards.

• Implications for Supply: Reliance on CMOs introduces potential variability, necessitating robust oversight and quality audits, especially given recent increases in regional supply disruptions.

3. API Suppliers

The active pharmaceutical ingredient, dexmethylphenidate, forms the core of Focalin XR. The API sourcing is a critical component of supply chain resilience.

• Major API Suppliers: Global API producers, such as Suzhou Huili Pharmaceutical Co. (China), Zhejiang Hisun Pharmaceutical Co., Ltd. (China), and Dr. Reddy’s Laboratories (India), supply dexmethylphenidate. These suppliers are generally approved by regulatory agencies, with some targeting both generic and branded formulations.

• Regulatory Compliance: API suppliers must meet strict quality standards (e.g., ISO, cGMP) for inclusion in FDA- or EMA-approved Focalin XR formulations.

---

Distribution Channels and Market Suppliers

1. Wholesalers and Distributors

Focalin XR is distributed through a well-established network of pharmaceutical wholesalers, national drug distributors, and pharmacy benefit managers (PBMs). These entities serve as the primary interface between manufacturers and end-users.

• Major Wholesalers: McKesson, Cardinal Health, and AmerisourceBergen act as principal distributors in the U.S., sourcing from Novartis and approved CMOs.

• Generic Manufacturers: While Novartis is the original innovator, generic manufacturers such as Teva Pharmaceuticals, Mylan (now part of Viatris), and Sun Pharmaceutical produce generic dexmethylphenidate formulations under licensing agreements. These generics often serve as alternative suppliers when patent exclusivity expires.

2. Generic Market Suppliers

Patent exclusivity for Focalin XR provided a period of market exclusivity; however, generic manufacturers have increasingly entered the space.

• Generic Equivalents: Companies like Sandoz and Aurobindo Pharma have secured approval for generic dexmethylphenidate ER formulations, supplying a significant portion of demand in the US and Europe.

• Implication for Supply: The presence of multiple generic sources stabilizes the supply but also introduces variability in manufacturing quality and regulatory standards, which companies need to monitor closely.

---

Regulatory and Market Influences on Supply Chain

Regulatory approvals and patent statuses significantly impact supplier dynamics.

• Patent Expiry and Generics: The patent for Focalin XR expired in 2014 in many markets, catalyzing the rise of generic competitors. This has expanded the supplier base but also introduced market competition risks and price pressures.

• Regulatory Approvals: Suppliers and manufacturers must navigate complex regulatory pathways for approval in different regions, which influence their ability to supply Focalin XR.

• Supply Disruptions: Recent global events such as the COVID-19 pandemic have disrupted supply chains, especially affecting API production and manufacturing throughput in regions heavily reliant on specific suppliers.

---

Supply Chain Risks and Management

1. Geopolitical and Economic Factors

Supply chains are vulnerable to geopolitical tensions, such as trade disputes or export restrictions, particularly concerning API imports from China and India.

2. Quality Control

Manufacturers and suppliers must maintain rigorous quality standards to prevent supply rejects or recalls, which can lead to shortages.

3. Raw Material Availability

The sourcing of chemical precursors for dexmethylphenidate API is subject to raw material price fluctuations and environmental regulations that can hinder supply continuity.

4. Inventory Management

Given the critical therapeutic role of Focalin XR, pharmaceutical companies employ strategic inventory buffers and diversified supplier networks to mitigate shortages.

---

Emerging Trends and Future Outlook

• Manufacturing Diversification: Companies are investing in expanding manufacturing capacity in North America and Europe to reduce dependence on Asian API producers.

• Regulatory Harmonization: Juggling multiple regulatory frameworks influences supplier selection, with a move towards harmonized requirements aimed at streamlining approvals.

• Supply Chain Digitization: Adoption of supply chain management platforms and blockchain technology enhances traceability, quality assurance, and response times.

• Sustainability Initiatives: Increasing emphasis on green manufacturing practices affects supplier selection and production planning.

---

Key Takeaways

• Novartis remains the primary manufacturer of Focalin XR, with a complex web of contract manufacturers and API suppliers contributing to supply stability.

• The increase in generic competition has broadened the supplier base but necessitates diligent quality and regulatory oversight.

• Supply chain disruptions—especially related to API sourcing and manufacturing capacity—pose ongoing risks, emphasizing the importance of diversified sourcing strategies.

• Geopolitical and regulatory factors are critical considerations influencing supplier choice and logistics planning.

• Strategic investments in manufacturing capacity and supply chain transparency are vital for ensuring continuous availability of Focalin XR.

---

FAQs

Q1: Who are the main suppliers of Focalin XR’s active pharmaceutical ingredient (API)?
A: Primary API suppliers include Chinese manufacturers like Suzhou Huili Pharmaceutical and Zhejiang Hisun Pharmaceutical, alongside Indian producers such as Dr. Reddy’s Laboratories. These companies supply dexmethylphenidate under strict regulatory standards.

Q2: Can generic manufacturers supply Focalin XR?
A: Yes. Following patent expiration in many markets, generic manufacturers like Teva, Mylan (Viatris), and Sun Pharmaceutical produce equivalent dexmethylphenidate ER formulations, expanding supply options.

Q3: How do supply chain disruptions impact Focalin XR availability?
A: Disruptions in API production, manufacturing delays in CMOs, or logistical challenges can lead to shortages, affecting patient access and prompting companies to diversify suppliers and inventories.

Q4: What regulatory factors influence Focalin XR’s supply chain?
A: Regulatory approvals, patent laws, and quality standards govern manufacturing permissions. Changes in regulations can either enable or restrict supplier operations, influencing reliability.

Q5: What trends are shaping the future supply of Focalin XR?
A: Trends include manufacturing diversification, increased regional production capacity, digitization of supply chains, and sustainability initiatives aimed at enhancing efficacy and resilience.

---

References

[1] Novartis Pharmaceuticals. Focalin XR Product Information. (2022).
[2] U.S. Food & Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
[3] European Medicines Agency. Product Data Sheet for Dexmethylphenidate Extended-Release.
[4] MarketWatch. "Generic Dexmethylphenidate Market Trends." 2022.
[5] IHS Markit. "Global API Supply Chain Report." 2022.